EU’s Joint Research Centre (JRC) publishes study identifying chemical testing strategies that require fewer tests, reduce need for animal testing; based on data on biocide and plant protection products, could be expanded for use across other product types
ECHA report on alternatives to animal testing
Fourth report from the European Chemicals Agency (ECHA) finds little change since 2017, number of alternative testing adaptations continuing to increase; read-across most commonly applied followed by data-waiving and weight of evidence approaches
Workshop proceedings on animal testing alternatives
Journal publication presents summary of presentations and key messages from 2017 workshop focused on animal testing alternatives and strategies for food safety assessments
Scientists oppose EPA’s phase-out of animal testing
Large group of scientists denounce U.S. Environmental Protection Agency’s plans to end animal testing by 2035; dispute agency’s claims that better methods exist to predict hazards of chemicals; publish open letter available for signing
U.S. NTP meetings on alternative toxicological methods
U.S. National Toxicology Program’s Scientific Advisory Committee on Alternative Toxicological Methods holds meetings on September 5-6 and September 19-20, 2018; registration for first meeting now open
EFSA and JRC continue to collaborate
EFSA and EU Joint Research Centre reinforce cooperation in food and feed safety areas, including food contact materials
Hearing on predictive toxicology roadmap
FDA holds public hearing on its predictive toxicology roadmap, September 12, 2018; registration open until August 29, 2018; comments accepted after hearing until October 12, 2018
FDA roadmap for predictive toxicology
U.S. FDA publishes roadmap to further develop predictive toxicology methods for risk assessment; public workshop to be held
Regulatory status of non-animal approaches
U.S. NAS workshop suggests comparing non-animal tests to human, not rodent, data, predicts alternatives to soon replace whole-animal tests; ECHA sees “long-way” until regulatory acceptance of alternatives for complex endpoints